Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02087176
Recruitment Status : Terminated (The study was terminated early by the sponsor.)
First Posted : March 14, 2014
Results First Posted : June 14, 2016
Last Update Posted : June 14, 2016
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 plus antimitotic agent and Placebo plus an antimitotic agent in Previously Treated Non-Small-Cell Lung Cancer Patients

Condition or disease Intervention/treatment Phase
Previously Treated Non Small Cell Lung Cancer Drug: AZD1775 Drug: AZD1775 Placebo Drug: Antimitotic Agent Drug: pegfiligrastim Phase 2

Detailed Description:
This multicentre trial consists of an open-labelled single cohort lead-in (Part A) followed by a phase II double-blind, randomised, placebo-controlled comparison of AZD1775 (or placebo) and an antimitotic agent. Review by a central laboratory of fresh tumour or archival tumour samples will be required prior to study entry to assess TP53 mutation status. However, subjects will be allowed to enter the single cohort (Part A) regardless of TP53 mutation status (wild-type or mutant). In addition, patients in the single cohort Part A treatment group will be asked to consent to limited sample collections for assessment of pharmacokinetic parameters.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients
Study Start Date : March 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AZD 1775, antimitotic, pegfilgrastim
AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
Drug: AZD1775
AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Other Name: MK-1775; Neulasta

Drug: Antimitotic Agent
The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Other Name: antiimitotic agent

Drug: pegfiligrastim
Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Other Name: Neulasta

Placebo Comparator: Placebo + antimitotic + pegfilgrastim
Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
Drug: AZD1775 Placebo
Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Other Name: MK-1775; Neulasta

Drug: Antimitotic Agent
The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Other Name: antiimitotic agent

Drug: pegfiligrastim
Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
Other Name: Neulasta




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Up to 20 months ]
    Response evaluation is determined by using Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions assessed by medical imaging scan (e.g. CT or MRI). The same method of assessment and the same technique was to be used to characterize each identified and reported lesion at baseline and during subsequent imaging procedures. The objective response rate is defined as the percentage of patients with a confirmed best overall response of Complete Response (CR) or Partial Response (PR). Complete Response is defined as disappearance of all target lesions since baseline. Any pathological lymph nodes selected as target lesions must have a reduction in short axis to < 10 mm. Partial Response is defined as at least a 30% decrease in the sum of the diameters of the Target Lesion, taking as reference the baseline sum of diameters.


Secondary Outcome Measures :
  1. Pharmacokinetic Profile of AZD 1775 in Combination With Docetaxel [ Time Frame: Up to projected 20 months, subjects will be restaged after every 2 cycles (every 6 weeks.) continue until disease progression or unacceptable toxicity ]
    Venous blood samples taken for determination of AZD1775, metabolites of 1775 on Cycle 1, Day 1 pre-dose and 2 hours post dose, Cycle 2 Day 1 pre-dose and 2 hours post dose, and Cycle 4 pre-dose and 2 hours post dose. However, the study was terminated early by the sponsor; therefore, pharmacokinetic data were not collected.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Provision of informed consent prior to any study specific procedures
  • Histologic or cytologic diagnosis of advanced NSCLC, excluding large cell neuroendocrine, and mixed NSCLC/small-cell histologies
  • Failure of one prior platinum-based doublet treatment for advanced NSCLC (either due to progressive disease or toxicity)
  • Measurable disease as measured by Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Mandatory availability of tumour tissue (archival or fresh if archival is not available) for TP53 testing
  • Male or female ≥18 years-of-age
  • Subjects may have received radiation for palliation prior to starting study treatment if they have recovered from the side effects of such therapy
  • Absolute neutrophil count (ANC) ≥1500/μL
  • Haemoglobin (Hgb) ≥9 g/dL
  • Platelets ≥100,000/uL
  • Adequate liver function defined as:
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits (WNL) or ≤2.5 x upper limit of normal (ULN), if liver metastases are present
  • Serum bilirubin WNL
  • Adequate renal function
  • Ability to swallow oral medication
  • Fertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops
  • Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures
  • Predicted life expectancy ≥12 weeks
  • Willingness and ability to comply with study and follow-up procedures
  • Ability to understand the investigational nature of this study and give written informed consent
  • Most recent chemotherapy ≤21 days or have not recovered from the side effects > Grade 1.
  • Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to the first dose of AZD1775
  • Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting AZD1775 or has not recovered from side effects of such therapy
  • Major surgical procedures ≤28 days of beginning AZD1775, or minor surgical procedures ≤7 days
  • Known central nervous system (CNS) disease
  • Any known hypersensitivity or contraindication to the components of study treatment (AZD1775 and docetaxel)
  • Any of the following cardiac diseases currently or within the last 6 months as defined by New York Heart Association [NYHA] ≥ Class 2
  • Pregnant or lactating
  • Concurrent administration of medications or foods that are strong inhibitors of
  • Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the subject to receive protocol treatment
  • Presence of other active cancers, or history of treatment for invasive cancer ≤3 years
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02087176


Locations
Layout table for location information
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, Arkansas
Research Site
Fayetteville, Arkansas, United States
United States, Colorado
Research Site
Englewood, Colorado, United States
United States, Florida
Research Site
Orlando, Florida, United States
United States, Kansas
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Louisville, Kentucky, United States
United States, North Carolina
Research Site
Durham, North Carolina, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Pennsylvania
Research Site
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Wisconsin
Research Site
Milwaukee, Wisconsin, United States
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Chair: David R Spigel, MD SCRI Development Innovations, LLC
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02087176    
Other Study ID Numbers: D6011C00001
First Posted: March 14, 2014    Key Record Dates
Results First Posted: June 14, 2016
Last Update Posted: June 14, 2016
Last Verified: April 2016
Keywords provided by AstraZeneca:
NSCLC
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antimitotic Agents
MK-1775
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Mitosis Modulators
Antineoplastic Agents